Urothelial Carcinoma and Its Metastatic Forms: Medical Treatments Today and Tomorrow

被引：1
作者：
Lavaud, P. [1 ]
Gizzi, M. [1 ]
Loriot, Y. [1 ]
机构：
[1] Gustave Roussy, Grand Paris, Dept Med Oncol, F-94805 Villejuif, France
来源：
ONCOLOGIE | 2015年 / 17卷 / 04期
关键词：
Urothelial carcinoma; Metastatic; Chemotherapy; Targeted therapies; Immunotherapy; TRANSITIONAL-CELL CARCINOMA; PHASE-III TRIAL; HEAT-SHOCK PROTEINS; PROGNOSTIC-FACTORS; CANCER; CISPLATIN; METHOTREXATE; GEMCITABINE; VINBLASTINE; DOXORUBICIN;
D O I：
10.1007/s10269-015-2505-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Urothelial carcinoma remains one of the most common and lethal disease in males. The combination of gemcitabine plus cisplatin with the MVAC regimen is used as first-line chemotherapy for advanced urothelial carcinoma. For unfit patients, the combination of carboplatin and gemcitabine is the preferred option. Currently, there is no standard therapy for patients who failed after first-line platinum-based chemotherapy, although vinflunine has been approved in this setting. However, recent advances in understanding the biological background of urothelial carcinomas have led to new hopes in metastatic disease, mainly with the new immune checkpoint inhibitors (PD-1 and PD-L1 inhibitors). Future strategies targeting the genomic alterations will be assessed in the coming years.
引用
收藏
页码：178 / 183
页数：6
相关论文
共 28 条
  • [21] A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102
    Philips, G. K.
    Halabi, S.
    Sanford, B. L.
    Bajorin, D.
    Small, E. J.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 (06) : 1074 - 1079
  • [22] MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
    Powles, Thomas
    Eder, Joseph Paul
    Fine, Gregg D.
    Braiteh, Fadi S.
    Loriot, Yohann
    Cruz, Cristina
    Bellmunt, Joaquim
    Burris, Howard A.
    Petrylak, Daniel P.
    Teng, Siew-Leng
    Shen, Xiaodong
    Boyd, Zachary
    Hegde, Priti S.
    Chen, Daniel S.
    Vogelzang, Nicholas J.
    [J]. NATURE, 2014, 515 (7528) : 558 - +
  • [23] A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours
    Schoffski, Patrick
    Awada, Ahmad
    Dumez, Herlinde
    Gil, Thierry
    Bartholomeus, Sylvie
    Wolter, Pascal
    Taton, Martine
    Fritsch, Holger
    Glomb, Patricia
    Munzert, Gerd
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 (02) : 179 - 186
  • [24] Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours
    Sternberg, CN
    de Mulder, P
    Schornagel, JH
    Theodore, C
    Fossa, SD
    van Oosterom, AT
    Witjes, JA
    Spina, M
    van Groeningen, C
    Duclos, B
    Roberts, JT
    de Balincourt, C
    Collette, L
    [J]. EUROPEAN JOURNAL OF CANCER, 2006, 42 (01) : 50 - 54
  • [25] Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy amd recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors:: European organization for research and treatment of cancer protocol no. 30924
    Sternberg, CN
    de Mulder, PHM
    Schornagel, JH
    Théodore, C
    Fossa, SD
    van Oosterom, AT
    Witjes, F
    Spina, M
    van Groeningen, CJ
    de Balincourt, C
    Collette, L
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (10) : 2638 - 2646
  • [26] Gemcitabine and cisplatin versus methotrexate vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large randomized, multinational, multicenter, phase III study
    von der Maase, H
    Hansen, SW
    Roberts, JT
    Dogliotti, L
    Oliver, T
    Moore, MJ
    Bodrogi, I
    Albers, P
    Knuth, A
    Lippert, CM
    Kerbrat, P
    Rovira, PS
    Wersall, P
    Cleall, SP
    Roychowdhury, DF
    Tomlin, I
    Visseren-Grul, CM
    Conte, PF
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) : 3068 - 3077
  • [27] Comprehensive molecular characterization of urothelial bladder carcinoma
    Weinstein, John N.
    Akbani, Rehan
    Broom, Bradley M.
    Wang, Wenyi
    Verhaak, Roeland G. W.
    McConkey, David
    Lerner, Seth
    Morgan, Margaret
    Creighton, Chad J.
    Smith, Carolyn
    Kwiatkowski, David J.
    Cherniack, Andrew D.
    Kim, Jaegil
    Pedamallu, Chandra Sekhar
    Noble, Michael S.
    Al-Ahmadie, Hikmat A.
    Reuter, Victor E.
    Rosenberg, Jonathan E.
    Bajorin, Dean F.
    Bochner, Bernard H.
    Solit, David B.
    Koppie, Theresa
    Robinson, Brian
    Gordenin, Dmitry A.
    Fargo, David
    Klimczak, Leszek J.
    Roberts, Steven A.
    Au, Jessie
    Laird, Peter W.
    Hinoue, Toshinori
    Schultz, Nikolaus
    Ramirez, Ricardo
    Hansel, Donna
    Hoadley, Katherine A.
    Kim, William Y.
    Damrauer, Jeffrey S.
    Baylin, Stephen B.
    Mungall, Andrew J.
    Robertson, A. Gordon
    Chu, Andy
    Kwiatkowski, David J.
    Sougnez, Carrie
    Cibulskis, Kristian
    Lichtenstein, Lee
    Sivachenko, Andrey
    Stewart, Chip
    Lawrence, Michael S.
    Getz, Gad
    Lander, Eric
    Gabriel, Stacey B.
    [J]. NATURE, 2014, 507 (7492) : 315 - 322
  • [28] Prognostic significance of heat shock proteins in urothelial carcinoma of the urinary bladder
    Yu, Hui-Jung
    Chang, Yen-Hwa
    Pan, Chin-Chen
    [J]. HISTOPATHOLOGY, 2013, 62 (05) : 788 - 798
123